US does not approve AstraZeneca for chronic nasal disease

AstraZeneca said the US regulator has refused to approve the asthma drug Fasenra for the treatment of chronic rhinosinusitis with nasal polyps, a condition characterized by benign growths that cause pain and congestion.

Share this post:

Share on facebook
Share on twitter
Share on pinterest
Share on whatsapp
Related Posts
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore
WordPress Cookie Plugin by Real Cookie Banner